Figure 2
Modulation of adjuvant arthritis (AA) development after nasal treatment with matrix metalloproteinase (MMP) peptides after AA induction. The nasal treatment was started at day +11, after immunization with Mycobacterium tuberculosis, when more than 50% of the animals showed weight loss (i.e. at the onset of clinical arthritis). The nasal treatment was repeated four times (arrows). Data shown are mean arthritis scores ± standard error of the mean of five rats (MMP-10 and MMP-16 peptide groups) or 10 rats (MMP-3 peptide group) per group. OVA323–339, ovalbumin peptide.